Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Clinical Trials, Intermediate Risk Prostate Cancer

PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05683691
Phase: Not Applicable
Trial Summary: The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device (“Vanquish”) in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Francis Medical Inc.
Acronym
: VAPOR 2

Pin It on Pinterest